Practical Considerations for Implementation of ¹⁷⁷Lu-DOTATATE Neuroendocrine Tumor Treatment Programs.

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Neuroendocrine tumors (NETs), particularly Gastroenteropancreatic (GEP) NETs, overexpress somatostatin subtype receptor 2.
• ¹⁷⁷Lu-DOTATATE, a novel peptide receptor radiopharmaceutical therapy (PRRT), was approved by the FDA in 2018.
• This therapy targets SSTR-positive NETs, marking a significant advancement in orphan disease treatment.

Purpose of the Study:

• To review the clinical considerations for establishing a ¹⁷⁷Lu-DOTATATE treatment program.
• To provide a comprehensive overview of implementing this advanced NET therapy.

Main Methods:

• Review of receptor-based NET radiopharmaceuticals.
• Analysis of ¹⁷⁷Lu-DOTATATE patient selection criteria and administration.
• Examination of clinical, regulatory, and radiation safety factors.
• Assessment of technical aspects, tissue dosimetry, and reimbursement.

Main Results:

• ¹⁷⁷Lu-DOTATATE has significantly impacted NET patient management.
• The implementation of a PRRT program requires careful consideration of multiple factors.
• Successful program implementation necessitates a multidisciplinary approach.

Conclusions:

• ¹⁷⁷Lu-DOTATATE represents a paradigm shift in treating SSTR-positive NETs.
• Effective implementation hinges on addressing patient selection, administration, safety, and logistics.
• This review provides essential guidance for healthcare providers offering this innovative therapy.